Detalhe da pesquisa
1.
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Br J Cancer
; 100(5): 671-5, 2009 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19223900
2.
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ann Oncol
; 20(11): 1787-93, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19542250
3.
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Ann Oncol
; 20(1): 27-33, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18695026
4.
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Eur J Cancer
; 51(16): 2275-84, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296295
5.
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
J Clin Pathol
; 61(8): 891-6, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18495790
6.
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
Br J Cancer
; 98(6): 1029-33, 2008 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-18349817